OXB
NEUTRALOxford Biomedica Announces Director's Associate Transaction
The healthcare company has announced a transaction by a person closely associated with a director.
Oxf Biomedica
286.00GBX
3.25%
Market Cap
328.32M
Volume
27.81k
10% of avg
P/E Ratio
-0.11
EPS (TTM)
-25.85
Beta
0.96
Day Range
0.00p - 0.00p
52 Week Range
0.00p286.00p455.00p
286.00p
Upcoming Events
11 June 2025
Annual General Meeting
End of 2026
Target to achieve Operating EBITDA margins of approximately 20%
High Impact Event
OXB
NEUTRALOxford Biomedica Announces Holding Change
The biotechnology company has disclosed a change in major shareholding, with Briarwood Chase Management LLC now holding over 12% of the company's shares.
OXB
NEUTRALOxford Biomedica Announces 2025 Annual General Meeting
The biotechnology company has announced the date and details for its 2025 Annual General Meeting.
OXB
NEUTRALOxford Biomedica Announces Major Shareholding Change
The biotechnology company has reported a change in major shareholding, with Briarwood Chase Management LLC now holding over 11% of the voting rights.
OXB
NEUTRALOxford Biomedica Reports 44% Revenue Growth, But Losses Continue
The cell and gene therapy CDMO reported strong revenue growth but continued losses. Despite positive client momentum, cash burn and economic uncertainties pose challenges for future performance.
OXB
NEUTRALOxford Biomedica Announces Major Shareholding Change
The biotechnology company has announced a significant change in its major shareholding structure.
OXB
NEUTRALOxford Biomedica Announces Director Appointment
The biotechnology company has appointed a new non-executive director to its board.
OXB
NEUTRALOxford Biomedica to Present at Leerink Conference
The biotechnology company will present at an upcoming healthcare conference, providing an opportunity to engage with investors.
OXB
NEUTRALOxford Biomedica Sees Increased Institutional Investment
The biotechnology company has seen a small increase in institutional investment, but the overall impact is neutral.
OXB
GOODOXB's Lentiviral Vectors to Support Boehringer Ingelheim's Gene Therapy Trial for Cystic Fibrosis
The biotechnology company's proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim's newly initiated Phase I/II trial of a gene therapy for cystic fibrosis, building on their successful long-term collaboration.